---
title: "Ascentage Pharma Sets Up US$200 Million Nasdaq ATM Offering Following SEC Shelf Filing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293216532.md"
description: "Ascentage Pharma filed an SEC shelf registration to launch a $200 million at-the-market equity offering on Nasdaq. This move aims to enhance funding capacity while complying with U.S. and Hong Kong regulations. Analysts maintain a 'Buy' rating with a $45 price target, though AI analysis flags the stock as 'Underperform' due to persistent losses and cash burn despite revenue growth."
datetime: "2026-07-20T12:48:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293216532.md)
  - [en](https://longbridge.com/en/news/293216532.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293216532.md)
---

# Ascentage Pharma Sets Up US$200 Million Nasdaq ATM Offering Following SEC Shelf Filing

Ascentage Pharma Group International Unsponsored ADR ( (AAPG) ) has provided an update.

On July 20, 2026, Ascentage Pharma Group International announced that it had filed an automatic shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission as a well-known seasoned issuer, enabling future offerings of American depositary shares representing its ordinary shares. The filing underpins a proposed at-the-market equity offering program of up to US$200 million in ADSs on Nasdaq, governed by a sales agreement with Citigroup, Deutsche Bank and BTIG, with issuance to be flexibly timed, subject to blackout-period, inside-information and Hong Kong listing-rule waiver constraints, potentially enhancing the company’s funding capacity while aligning with regulatory requirements in both the U.S. and Hong Kong.

The most recent analyst rating on (AAPG) stock is a Buy  
with a $45.00 price target.  
To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock,  
see the AAPG Stock Forecast page.

**Spark’s Take on AAPG Stock**

According to Spark, TipRanks’ AI Analyst, AAPG is a Underperform.

The score is primarily constrained by weak financial performance driven by persistent and worsening losses and significant cash burn, despite strong revenue growth and high gross margins. Technicals also reflect a weak trend with negative momentum. Valuation is further pressured by a negative P/E and no dividend yield data.

To see Spark’s full report on AAPG stock,  
click here.

**More about Ascentage Pharma Group International Unsponsored ADR**

Ascentage Pharma Group International is a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong and trading American depositary shares on Nasdaq. The group focuses on developing and commercializing innovative oncology therapies, leveraging dual listings to access both Asian and U.S. capital markets and investor bases.

**Average Trading Volume:** 11,672

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $1.69B

For an in-depth examination of AAPG stock, go to TipRanks’ Overview page.

### Related Stocks

- [AAPG.US](https://longbridge.com/en/quote/AAPG.US.md)
- [06855.HK](https://longbridge.com/en/quote/06855.HK.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [DB.US](https://longbridge.com/en/quote/DB.US.md)
- [DBK.DE](https://longbridge.com/en/quote/DBK.DE.md)
- [AAPGV.US](https://longbridge.com/en/quote/AAPGV.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)
- [03KB.DE](https://longbridge.com/en/quote/03KB.DE.md)
- [DPB.DE](https://longbridge.com/en/quote/DPB.DE.md)

## Related News & Research

- [Ascentage Pharma Sets Up $200 Million Nasdaq ATM Offering Program](https://longbridge.com/en/news/293123151.md)
- [Netcapital says SEC stay halts Nasdaq $5 million market-value delisting rule pending review](https://longbridge.com/en/news/294513835.md)
- [Governance Red Flags at U.S. Gold Corp: Control Weaknesses, Late SEC Filings and Nasdaq Compliance Risk](https://longbridge.com/en/news/294476139.md)
- [Does Viking’s Expanded Shelf and ATM Funding Shift the Bull Case For Viking Therapeutics (VKTX)?](https://longbridge.com/en/news/294783383.md)
- [SEC keeps Nasdaq bitcoin options on hold after granting CME review](https://longbridge.com/en/news/294613840.md)